Anti-FGF19 Antibody (1A6) represents a highly specialized monoclonal antibody specifically engineered to target the human fibroblast growth factor 19 with exceptional binding affinity. It effectively facilitates the measurable neutralization of FGF19-mediated signaling across various preclinical experimental models to evaluate the blockade of the FGFR4/beta-Klotho complex during strictly monitored laboratory observation periods and functional cell signaling assays to ensure high experimental sensitivity in molecular oncology.